The global value of the synthetic biology market reached $1.1 billion in 2010. It is expected to reach $1.6 billion in 2011 and it will further grow to $10.8 billion by 2016, increasing at a compound annual growth rate (CAGR) of 45.8.%.
Download Free Chapter
SCOPE AND FORMAT
The study’s scope includes core synthetic biology products (synthetic genes, other DNA parts, chassis organisms, synthetic cells), enabling technologies (DNA sequencing, oligonucleotides, specialty media, bioinformatics), and enabled technologies (biofuels, specialty chemicals, diagnostics, pharmaceuticals, agriculture) that are already commercial or forecast to be commercialized within the next 5 years.
We analyze key synthetic biology technologies and products to determine present and future market status, and forecast growth from 2011 through 2016. We also discuss strategic alliances, industry structures, competitive dynamics, patent strategy, and market driving forces.
BCC examines the synthetic biology industry by market segment, including suppliers of synthetic genes, enzymes, pharmaceutical companies, biofuels, and specialty chemicals. The role of key strategic alliances from 2009 through 2011 is discussed. Emerging markets including synthetic genes, synthetic biology-enabled drugs and vaccines, and chassis organisms are analyzed, as well as metabolically-engineered factories for producing synthetic fuels and specialty chemicals. The main companies in these fields are highlighted.
The author, John Bergin, has written previous BCC biotechnology reports entitled Epigenomics: Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics; Global Biochip Markets: Microarrays and Lab-on-a-chip; RNA Interference in the Post-Genomics Era: Markets and Technologies; DNA Sequencing: Emerging Technologies and Markets; and Biologic Imaging Reagent: Future Technologies and Markets. Mr. Bergin has held business development, sales, and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with an emerging nanotechnology company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology, and Masters of Business Administration.